Blood Cancer Journal最新文献

{"title":"Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.","authors":"Yucai Wang,Melissa C Larson,Steven R Hwang,Diego Villa,Laveniya Kugathasan,Anita Kumar,Ashlee Joseph,Taylor R Brooks,Brian T Hill,David A Bond,Kami J Maddocks,Alexey Danilov,Christine Argao,Jia Ruan,Imran A Nizamuddin,Brad S Kahl,Natalie S Grover,Nazneen B Khan,Georgios N Pongas,Izidore S Lossos,Evguenia Ouchveridze,Aung M Tun,Firas Baidoun,Muhamad Alhaj Moustafa,Zoey I Harris,Javier L Munoz,Philip R Young,Craig A Portell,Patrick M Reagan,Christine E Ryan,Reid W Merryman,Arash Velayati,I Brian Greenwell,Drew G Gerber,Preetesh Jain,Michael L Wang,Sabarish R Ayyappan,Eric Mou,Lauren G Banaszak,Priyanka A Pophali,Anthony C Stack,Marcus R Messmer,Mayur S Narkhede,Amitkumar Mehta,Tamara K Moyo,Nilanjan Ghosh,Rahul S Bhansali,Stefan K Barta,Manali K Kamdar,Jacob Anna,Alexander V Stanisic,Reem Karmali,Matthew J Maurer,James R Cerhan,Jonathon B Cohen,Peter Martin","doi":"10.1038/s41408-026-01507-w","DOIUrl":"https://doi.org/10.1038/s41408-026-01507-w","url":null,"abstract":"Addition of Bruton's tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020. Event-free survival (EFS), EFS2, and overall survival (OS) were analyzed. By intention-to-treat (ITT), EFS2 was defined as time from 1 L BR start to progression/relapse or retreatment following 2 L BTKi or death. After a median follow-up of 61.4 (95% CI 56.4-65.9) months, the median EFS after 1 L BR was 34.2 (95% CI 31.5-38.4) months. The median EFS2 following 1 L BR and 2 L BTKi by ITT analysis was 64.8 (95% CI 56.7-82.8) months, and the 5-year OS rate after 1 L BR was 57.9% (95% CI 54.1-62.0%), close to SHINE and ECHO results. Patients without high-risk features (high simplified MIPI, high Ki-67, blastoid/pleomorphic morphology, TP53 mutation, or complex karyotype) had more favorable survival outcomes. These results suggest that sequential treatment with 1 L BR and 2 L BTKi remains reasonable for select patients with MCL, particularly those without high-risk features.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"2 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147743895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes.","authors":"R Parikh,R P Thirugnanasambandam,U A Shah","doi":"10.1038/s41408-026-01504-z","DOIUrl":"https://doi.org/10.1038/s41408-026-01504-z","url":null,"abstract":"There is a clear link between type 2 diabetes mellitus (DM) and overall cancer risk. However, studies evaluating type 2 DM and multiple myeloma (MM) risk are limited, and the association is less clear. Understanding the impact of longstanding type 2 DM on organ systems and symptomatology in patients with a subsequent MM diagnosis, alongside potential overlapping toxicities from MM treatment, is crucial. This review summarizes the role of type 2 DM on MM risk and outcomes and explores the various mechanisms underlying these associations. A better understanding of this association will help improve outcomes in diabetic MM patients through lifestyle and drug related interventions. Clinical trial registration: Not applicable.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"54 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147738966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoalbuminemia in MGUS: interpreting a prognostic signal within its biological context.","authors":"Michele Bibas","doi":"10.1038/s41408-026-01490-2","DOIUrl":"https://doi.org/10.1038/s41408-026-01490-2","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"13 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147738965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study.","authors":"John L Vaughn, Malak Munir, Ashley Cobb, Sravani Rimmalapudi, Narendranath Epperla","doi":"10.1038/s41408-026-01505-y","DOIUrl":"https://doi.org/10.1038/s41408-026-01505-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":11.6,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13106755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147761439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.","authors":"Joshua N Gustine,Narsis Attar,Benjamin R Puliafito,Diana D Cirstea,Andrew R Branagan,Andrew J Yee,Noopur S Raje","doi":"10.1038/s41408-026-01510-1","DOIUrl":"https://doi.org/10.1038/s41408-026-01510-1","url":null,"abstract":"The new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (MM) was recently updated by the International Myeloma Society and International Myeloma Working Group. We performed a retrospective study to validate the revised HRMM criteria in relapsed and refractory MM patients treated with BCMA CAR-T. A total of 158 patients were included, of whom 75 (47%) met criteria for HRMM. The median follow-up was 24.8 months (95% CI 22.5-30.3). On multivariable analysis, patients with HRMM had significantly shorter PFS (HR 1.89, p = 0.003) and OS (HR 3.06, p < 0.001) compared to standard-risk MM (SRMM) following BCMA CAR-T. LDH > 210 U/L and EMD were also identified as independent adverse risk factors. Based on survival analyses, we constructed a reclassified staging system incorporating LDH and EMD into the CGS-HRMM criteria. Patients were divided into four discrete risk groups: low risk (SRMM with normal LDH and no EMD; n = 42, 26%), intermediate-low risk (HRMM with normal LDH and no EMD; n = 31, 20%), intermediate-high risk (SRMM with high LDH, EMD, or both; n = 41, 26%), and high risk (HRMM with high LDH, EMD, or both; n = 44, 28%). Patients with low, intermediate-low, intermediate-high, and high-risk disease had a median PFS of 35.0, 19.6, 10.4, and 6.6 months, respectively (p < 0.0001), and an estimated 24-month OS of 90%, 69%, 66%, and 26%, respectively (p < 0.0001). In summary, we validated the new CGS-HRMM criteria in relapsed and refractory MM patients treated with BCMA CAR-T. We also propose a reclassified staging system to further improve risk stratification in MM patients treated with BCMA CAR-T.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"32 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147733379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response","authors":"Mikhail Roshal, Isabella Y. Kong, Wikum Dinalankara, Jonathan B. Reichel, Matthew Teater, Bhavneet Binder, Sakellarios Zairis, Joshua D. Brody, Sunita I. Park, Alexandra E. Kovach, Nitya Gulati, Matthew J. Oberley, Megan S. Lim, Matthew J. Barth, Olivier Elemento, Ari Melnick, Raul Rabadan, Amy Chadburn, Luigi Marchionni, Lisa Giulino-Roth, Ethel Cesarman","doi":"10.1038/s41408-026-01502-1","DOIUrl":"https://doi.org/10.1038/s41408-026-01502-1","url":null,"abstract":"Classic Hodgkin lymphoma (cHL) shares mutations with primary mediastinal B cell lymphoma (PMBL) but differs in histology, clinical behavior, and phenotype. To define transcriptional programs underlying these differences, we performed flow cytometric cell sorting and low-input RNA sequencing of Hodgkin and Reed-Sternberg (HRS) cells from eighteen primary tumors, paired intra-tumoral B cells, and four cHL cell lines, and compared them with RNA-sequencing data from 40 PMBL cases. Transcriptomic profiling revealed that HRS cells undergo abortive plasma cell differentiation with robust activation of the unfolded protein response (UPR), a feature shared with multiple myeloma but absent in diffuse large B cell lymphoma and PMBL. HRS cells also demonstrated profound immune evasion, including suppression of B cell identity genes and loss of natural killer cell recognition through downregulation of SLAM family ligands such as CD48. Comparative analysis with PMBL highlighted shared oncogenic programs and key distinctions: HRS cells exhibited greater loss of B cell identity, absence of GCB- and plasma cell markers, and unique upregulation of cytoskeletal and mitotic pathways consistent with their multinucleated morphology. These findings establish HRS cells as aberrantly differentiated GCB cells with partial plasmacytic features, UPR activation and distinct immune evasion strategies.\u0000\u0000The alternative text for this image may have been generated using AI.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"1 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed-duration cytarabine consolidation improves relapse-free survival over indefinite AZA-VEN in younger AML.","authors":"Rudra Narayan Swain,Arihant Jain,Sarthak Wadhera,Charanpreet Singh,Aditya Jandial,Alka Khadwal,Man Updesh Sachdeva,Shano Naseem,Pankaj Malhotra,Gaurav Prakash","doi":"10.1038/s41408-026-01492-0","DOIUrl":"https://doi.org/10.1038/s41408-026-01492-0","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"22 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.","authors":"Doris K Hansen,Danai Dima,Hira Mian,Jakob Devos,Ruta Brazauskas,Temitope Oloyede,Aimaz Afrough,Nausheen Ahmed,Larry Anderson,Rahul Banerjee,Jesus G Berdeja,Aram Bidikian,Binod Dhakal,Ajoy Dias,Yvonne Efebera,Muhammad Salman Faisal,Lohith Gowda,Hamza Hashmi,Abu-Sayeef Mirza,Meera Mohan,Ravi Narra,Ashley E Rosko,Mark Schroeder,Taiga Nishihori,Heather Landau,Saad Usmani,Marcelo C Pasquini,Othman S Akhtar,Surbhi Sidana,Krina K Patel","doi":"10.1038/s41408-026-01496-w","DOIUrl":"https://doi.org/10.1038/s41408-026-01496-w","url":null,"abstract":"Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients reported to the Center for International Blood and Marrow Transplant Research registry between March 2022 and December 2023 who met commercial release specifications. Among 595 patients, median age was 64 years, 57% were male, and 70% had ≥1 comorbidity. Extramedullary disease and marrow plasma cell burden ≥ 50% were present in 13% and 14% of patients, respectively. The median number of prior lines of therapy was 7 and 8% had received prior BCMA-directed therapy. Median follow-up was 12 months (range, 1-25 months). Cytokine release syndrome occurred in 80% (≥ grade 3: 4%) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 22% (≥ grade 3: 4%). Non-ICANS neurotoxicity was seen in 5% (n = 31), including Parkinsonism in 2.7% (n = 16) and cranial nerve palsies in 2.5% (n = 15), primarily cranial nerve VII (n = 12/15). Infections occurred in 47% and treatment-related mortality was 5%. The best overall response rate was 87%, with ≥ very good partial response rate in 75%, and ≥ complete response rate in 35%. Estimated 12-month progression-free and overall survival were 73% (95% CI: 68-77%) and 85% (95% CI: 81-88%), respectively. This represents the largest standard-of-care (SOC) study of cilta-cel in RRMM patients to date. Despite advanced disease and high comorbidity burden, cilta-cel demonstrated favorable safety and efficacy, supporting its use in clinical practice.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"68 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.","authors":"Paul G Kemps,Jennifer L Picarsic,Sébastien Héritier,Jean Donadieu,Julien Haroche,Laure Farnault,Stefania Gaspari,Dmitry A Evseev,Daria S Osipova,Alexander E Druy,Milen Minkov,Susan Picton,Andreas Beilken,Robert Möhle,Miloš B Kuzmanović,Hitomi S Okuma,Chung W Chow,Martin A Campbell,Gregory S Phillips,Yuhang Zhou,Gaurav Goyal,Ronald S Go,Kee Kiat Yeo,Bryan A Sisk,Joanna L Weinstein,Patrick K Campbell,Eli L Diamond,Jean-François Emile","doi":"10.1038/s41408-026-01498-8","DOIUrl":"https://doi.org/10.1038/s41408-026-01498-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"10 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.","authors":"Christen M Dillard,Hans Lee,Nilesh Kalariya,Naveen Subramanian,Oren Pasvolsky,Christopher Ferreri,Mahmoud Gaballa,Sheeba K Thomas,Donna M Weber,Melody Becnel,Gregory Kaufman,Muzaffar Qazilbash,Robert Z Orlowski,Michelle A T Hildebrandt,Krina K Patel","doi":"10.1038/s41408-026-01489-9","DOIUrl":"https://doi.org/10.1038/s41408-026-01489-9","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"124 22 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147666525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}